A detailed history of Harbour Investments, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Harbour Investments, Inc. holds 110 shares of EXEL stock, worth $3,609. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110
Previous 100 10.0%
Holding current value
$3,609
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025

BUY
$25.39 - $36.46 $253 - $364
10 Added 10.0%
110 $3,000
Q3 2023

Nov 15, 2023

BUY
$19.04 - $22.74 $1,904 - $2,274
100 New
100 $2,000
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $69 - $92
4 New
4 $0
Q4 2021

Feb 16, 2022

SELL
$15.84 - $21.88 $15,048 - $20,786
-950 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$16.3 - $21.14 $3,260 - $4,228
200 Added 26.67%
950 $20,000
Q2 2021

Aug 16, 2021

BUY
$17.95 - $25.56 $9,872 - $14,058
550 Added 275.0%
750 $14,000
Q1 2021

Aug 17, 2021

BUY
$20.53 - $25.22 $4,106 - $5,044
200 New
200 $5,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.6B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Harbour Investments, Inc. Portfolio

Follow Harbour Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbour Investments, Inc. with notifications on news.